Search alternatives:
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
large increase » large increases (Expand Search), marked increase (Expand Search)
b larger » _ larger (Expand Search), _ large (Expand Search), a large (Expand Search)
ai large » a large (Expand Search), via large (Expand Search), _ large (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
i large » _ large (Expand Search), a large (Expand Search), via large (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
large increase » large increases (Expand Search), marked increase (Expand Search)
b larger » _ larger (Expand Search), _ large (Expand Search), a large (Expand Search)
ai large » a large (Expand Search), via large (Expand Search), _ large (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
i large » _ large (Expand Search), a large (Expand Search), via large (Expand Search)
-
121
-
122
-
123
-
124
-
125
-
126
Deletion of murine <i>Rhoh</i> leads to de-repression of <i>Bcl-6</i> via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma
Published 2022“…RHOH was initially identified as a translocation partner with BCL-6 in non-Hodgkin lymphoma (NHL), and aberrant somatic hypermutation (SHM) in the 5ʹ untranslated region of the RHOH gene has also been detected in Diffuse Large B-Cell Lymphoma (DLBCL). Recent data suggest a correlation between RhoH expression and disease progression in Acute Myeloid Leukaemia (AML). …”
-
127
-
128
DataSheet_1_Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.xlsx
Published 2021“…The genes most frequently altered (> 20%) were (in decreasing order of frequency) CDKN2A, PIM1, CD79B, TP53, MYD88, MYC, BTG2, BTG1, CDKN2B, DTX1, CD58, ETV6, and IRF4. …”
-
129
-
130
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
131
-
132
-
133
-
134
-
135
-
136
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
137
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
138
-
139
A model for elucidating the transovarial transmission of <i>N</i>. <i>bombycis</i>.
Published 2023Subjects: -
140